文献速递肥胖与代谢综合征糖尿病

新生儿巨大儿是科罗拉多州新生儿筛查中分析物的干扰因素

Neonatal Macrosomia is an Interfering Factor for Analytes on the Colorado State Newborn Screen.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究利用科罗拉多州公共卫生与环境部2016-2018年档案,比较出生体重2500-3999克(非巨大儿,n=131896)与4000-8000克(巨大儿,n=7806)新生儿在24-72小时采集的串联质谱筛查分析物。巨大儿C2、C3、二羧酸及长链酰基肉碱(特别是C16和C18)升高,C3和C18:1超过州预设切值的可能性为非巨大儿的2至3倍。作者结论认为巨大儿是C3和C18:1的干扰因素,分别导致甲基丙二酸/丙酸血症和肉碱棕榈酰转移酶2型缺乏症的假阳性风险增高。

要点

  • 巨大儿C3和C18:1超过州预设切值的可能性为非巨大儿的2至3倍。
  • 巨大儿C2、C3、二羧酸及长链酰基肉碱(C16和C18)升高。
  • 巨大儿分析物模式与肥胖儿童和成人相似。

核心结论

  • 巨大儿是C3和C18:1的干扰因素,分别导致甲基丙二酸/丙酸血症和肉碱棕榈酰转移酶2型缺乏症的假阳性风险增高。

研究设计与样本

  • 研究采用串联质谱法测定科罗拉多州公共卫生与环境部档案(2016-2018年)中新生儿筛查分析物。
  • 纳入出生体重2500-3999克非巨大儿(n=131896)与4000-8000克巨大儿(n=7806),于生后24-72小时采集标本。
  • 母婴表型数据仅限于新生儿筛查干血斑卡上提供的信息,使用Student t检验和卡方分析。

主要发现

  • 巨大儿C2、C3、二羧酸及长链酰基肉碱(特别是C16和C18)升高。
  • 巨大儿(男女均)C3和C18:1超过州预设切值的可能性为非巨大儿的2至3倍。
  • 巨大儿分析物模式与肥胖儿童和成人相似。

局限性

  • 母婴表型数据仅限于新生儿筛查干血斑卡上提供的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neonatal macrosomia is a known complication of maternal obesity and gestational diabetes, and it is a risk factor for obesity and diabetes in offspring. Amino acids and acylcarnitines are biomarkers for obesity in children and adults. These analytes, which are also routinely obtained on the newborn screen, have not been well-characterized in macrosomic newborns. The impact of macrosomia on rates of false-positive results in the newborn screen has also not been well-studied. We test the hypothesis that macrosomia is an interfering factor for amino acids and/or acylcarnitines on the newborn screen. METHODS: Newborn screening analytes determined by tandem mass spectroscopy were obtained from the Colorado Department of Public Health and Environment archives (2016-2018). This included metabolite concentrations obtained at 24-72 hours of life from newborns with birth weight 2500 to 3999 g (nonmacrosomic, n = 131 896) versus 4000 to 8000 g (macrosomic, n = 7806). Mother/infant phenotypic data were limited to information provided on the newborn screening dried blood spot card. Data were analyzed using Student t-test and chi-squared analysis. RESULTS: Macrosomic newborns had elevations in C2, C3, dicarboxylic, and long-chain acylcarnitines (specifically C16 and C18 species). C3 and C18:1 were 2 to 3 times more likely to be above predetermined state cutoffs in macrosomic versus nonmacrosomic newborns (both male and female). MAIN CONCLUSIONS: Macrosomia is an interfering factor for the analytes C3 and C18:1, leading to higher risk of false-positive results for methylmalonic/propionic acidemia and carnitine palmitoyl transferase type 2 deficiency, respectively. Analyte patterns found in macrosomic neonates correspond with similar analyte patterns in obese children and adults.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wright EL, Baker PR. Neonatal Macrosomia is an Interfering Factor for Analytes on the Colorado State Newborn Screen. J Clin Endocrinol Metab. 2020. PMID: 32126138. doi:10.1210/clinem/dgz183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。